The Impact of Levetiracetam versus Phenytoin as Second-Line Therapy for Status Epilepticus in the Emergency Department: A Systematic Review
DOI:
https://doi.org/10.65759/kn392r20Keywords:
Status Epilepticus, Levetiracetam, Phenytoin, Second-Line Therapy, Emergency DepartmentAbstract
Background: After benzodiazepine failure, status epilepticus (SE), a neurological emergency, necessitates immediate second-line treatment. Levetiracetam and phenytoin are commonly used, However, there is ongoing discussion over their relative safety and effectiveness in the emergency department (ED). Objective: to thoroughly examine the safety and efficacy of intravenous levetiracetam against phenytoin as a second-line treatment for SE in the ED that is benzodiazepine-refractory. Methods: The PRISMA 2020 standards were followed in conducting a systematic review. We looked for papers (within the previous five years) comparing the two medicines in ED patients with SE in PubMed/MEDLINE, Scopus, and Web of Science. Efficacy outcomes were seizure cessation rate, time to cessation, and 24-hour recurrence. Safety outcomes included adverse events. The Cochrane RoB 2 and ROBINS-I tools were used to evaluate the risk of bias. Results: Five studies (three RCTs, one quasi-experimental, one retrospective cohort; total n=523), all in pediatric populations, were included. Results indicated comparable efficacy for initial seizure cessation, with rates ranging from 78.8% to 94% for levetiracetam and 74.3% to 90.5% for phenytoin. According to two trials, levetiracetam considerably shortened the time it took for seizures to stop. Recurrence rates within 24 hours showed no significant difference. Safety data were insufficiently reported, but qualitative findings favored levetiracetam's tolerability. considerable variability, open-label designs, and a considerable risk of bias in non-randomized trials reduced the overall strength of the evidence. Conclusion: Levetiracetam and phenytoin demonstrate similar efficacy for aborting benzodiazepine-refractory SE in the ED. The choice between them may be guided by levetiracetam's potential for faster administration, more favorable pharmacokinetics, and superior safety profile, consistent with findings from larger pragmatic trials. Higher-quality, standardized research is needed to strengthen these conclusions.
References
1. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015 Oct;56(10):1515-23.
2. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy currents. 2016 Jan;16(1):48-61.
3. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O'Neil N, Neuhaus JM, Segal MR, Lowenstein DH. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. New England Journal of Medicine. 2001 Aug 30;345(9):631-7.
4. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, LaRoche SM, Riviello Jr JJ, Shutter L, Sperling MR, Treiman DM. Guidelines for the evaluation and management of status epilepticus. Neurocritical care. 2012 Aug;17(1):3-23.
5. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage. Jama. 1983 Feb 11;249(6):762-5.
6. Abend NS, Bearden D, Helbig I, McGuire J, Narula S, Panzer JA, Topjian A, Dlugos DJ. Status epilepticus and refractory status epilepticus management. InSeminars in pediatric neurology 2014 Dec 1 (Vol. 21, No. 4, pp. 263-274).
7. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, Francis KL, Sharpe C, Harvey AS, Davidson A, Craig S. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. The Lancet. 2019 May 25;393(10186):2135-45.
8. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, Francis KL, Sharpe C, Harvey AS, Davidson A, Craig S. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. The Lancet. 2019 May 25;393(10186):2135-45.
9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021 Mar 29;372.
10. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj. 2019 Aug 28;366.
11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016 Dec 5;5(1):210.
12. Anjum ZM, Arshad MU, Khan MI, Iqbal A, Mushtaq A. Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health, Faisalabad. Pakistan Pediatric Journal. 2024;48(4).
13. Zaman S, Shuaib A, Shah SA, Zahid M, Khan QU, Murad M. Outcome of intravenous Levetiracetam versus intravenous phenytoin in Management of Children with status epilepticus. Pak Armed Forces Med J. 2022 Jun 1;72:779-82.
14. Köle MT, Sager SG, Zeynel H, Çağ Y, Akın Y. Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. Child's Nervous System. 2022 Jul;38(7):1357-64.
15. Naeem B, Ashfaq M, Qureshi MA. Efficacy of levetiracetam versus phenytoin as a second-line antiepileptic drug in the management of benzodiazepine-refractory status epilepticus among children. Journal of Ayub Medical College Abbottabad. 2023 Jul 9;35(3):410-4.
16. Kartek M, Kannan A, Anand V, Sahoo MR. Intravenous levetiracetam versus intravenous phenytoin as second Line treatment in pediatric convulsive status epilepticus-open label randomized controlled trial. Journal of Family Medicine and Primary Care. 2024 Aug 1;13(8):3368-73.
17. Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N. Randomized trial of three anticonvulsant medications for status epilepticus. New England Journal of Medicine. 2019 Nov 28;381(22):2103-13.
18. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, Francis KL, Sharpe C, Harvey AS, Davidson A, Craig S. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. The Lancet. 2019 May 25;393(10186):2135-45.
19. Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012 Sep;53:127-38.
20. Abend NS, Bearden D, Helbig I, McGuire J, Narula S, Panzer JA, Topjian A, Dlugos DJ. Status epilepticus and refractory status epilepticus management. InSeminars in pediatric neurology 2014 Dec 1 (Vol. 21, No. 4, pp. 263-274). WB Saunders.
21. Lyttle MD, Rainford NE, Gamble C, Messahel S, Humphreys A, Hickey H, Woolfall K, Roper L, Noblet J, Lee ED, Potter S. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet. 2019 May 25;393(10186):2125-34.
22. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, Francis KL, Sharpe C, Harvey AS, Davidson A, Craig S. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. The Lancet. 2019 May 25;393(10186):2135-45.
23. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, LaRoche SM, Riviello Jr JJ, Shutter L, Sperling MR, Treiman DM. Guidelines for the evaluation and management of status epilepticus. Neurocritical care. 2012 Aug;17(1):3-23.
